Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial)

Martha Finnegan, Karen Ryan, Enda Shanahan, Andrew Harkin, Leslie Daly, Declan M McLoughlin, Martha Finnegan, Karen Ryan, Enda Shanahan, Andrew Harkin, Leslie Daly, Declan M McLoughlin

Abstract

Background: Major depressive disorder is a common debilitating illness that is the second leading contributor to the global burden of disease. Unfortunately, about 30 % of patients do not respond to adequate trials of antidepressants and/or psychotherapies. About 45-60 % of such treatment-resistant patients will remit with electroconvulsive therapy (ECT). However, relapse rates are high following ECT-38 % after 6 months. There is a need for better relapse prevention strategies. One possibility is to use ketamine, a competitive glutamate receptor antagonist used for anaesthesia. A recent paradigm shift in treating depression and understanding its biology has been the finding that ketamine has a robust, rapid-onset, though short-lived, antidepressant effect that is possibly mediated through neuroplastic effects. However, ketamine has not previously been reported on for relapse prevention.

Methods/design: The main objective of this study is to conduct a randomised controlled pilot trial (n = 40) of a 4-week course of once-weekly ketamine infusions for relapse prevention following ECT for depression to assess trial procedures that will inform a future definitive trial. Participants with unipolar depression will be recruited prior to commencing ECT and be assessed weekly during the ECT course using the primary clinical outcome, the 24-item Hamilton Rating Scale for Depression (HRSD-24). Those who meet standard response criteria will be invited, on completing ECT, to be randomised in a 1:1 ratio to a course of four once-weekly infusions of ketamine or an active comparator midazolam, which mimics some of the effects of ketamine and may improve blinding over inactive placebo. Participants will be followed up over 6 months using the HRSD-24 to assess for relapse.

Discussion: This is the first registered trial (NCT02414932, https://ichgcp.net/clinical-trials-registry/NCT02414932) of ketamine for depression relapse prevention, an important possible use of this agent. The primary focus of the pilot trial is on feasibility. However, a 95 % confidence interval will be determined for the difference between ketamine and midazolam groups in 6-month relapse rates to help inform a future definitive trial.

Trial registration: https://ichgcp.net/clinical-trials-registry/NCT02414932" title="See in ClinicalTrials.gov">NCT02414932 Secondary Identifying numbers: EudraCT number: 2014-000339-18 Sponsors' Reference, Sponsor: St. Patrick's Mental Health Services: 05/14 Research Ethics Committee Reference, Joint REC of St James' and Tallaght Hospitals, Dublin: 2014-08-19.

Keywords: Depression; Electroconvulsive therapy; Ketamine; Pilot trial; Relapse prevention.

Figures

Fig 1
Fig 1
Consort diagram

References

    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. doi: 10.1001/archpsyc.62.6.593.
    1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–679. doi: 10.1016/j.euroneuro.2011.07.018.
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. doi: 10.1016/S0140-6736(12)61729-2.
    1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatr. 2006;163(11):1905–1917. doi: 10.1176/ajp.2006.163.11.1905.
    1. UKECTReviewGroup Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808. doi: 10.1016/S0140-6736(03)12705-5.
    1. Eranti S, Mogg A, Pluck G, Landau S, Purvis R, Brown RG, Howard R, Knapp M, Philpot M, Rabe-Hesketh S, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatr. 2007;164(1):73–81. doi: 10.1176/ajp.2007.164.1.73.
    1. Semkovska MLS, Dunne R, Kolshus E, Kavanagh A, Jelovac A, Noone M, Carton M, Lambe S, McHugh C, McLoughlin D. Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial. Am J Psychiatr. 2016. .
    1. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577. doi: 10.1016/j.biopsych.2010.06.009.
    1. Psychiatrists RCo . The ECT handbook, 3rd edition. 2013.
    1. Commission MH . The administration of ECT in approved centres: activity report 2012. 2014.
    1. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38:2467–2474. doi: 10.1038/npp.2013.149.
    1. Excellence NIfHaC . CG 90 Research Recommendations. 2009. Depression in adults: recognition and management.
    1. Geddes JRCS, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653–661. doi: 10.1016/S0140-6736(03)12599-8.
    1. Sackeim HA, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285(10):1299–1307. doi: 10.1001/jama.285.10.1299.
    1. Petrides G, et al. Continuation ECT: relapse prevention in affective disorders. J ECT. 1994;10(3):189–194.
    1. McGirr A, Berlim M, Bond D, Fleck M, Yatham L, Lam R. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(04):693–704. doi: 10.1017/S0033291714001603.
    1. Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi AA, Mitchell PB, Rodgers A. Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2016;19(4). Print 2016 Apr. doi:10.1093/ijnp/pyv124.
    1. Wan LB1, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247–52. doi: 10.4088/JCP.13m08852.
    1. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CM, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatr. 2013;170(10):1134–1142. doi: 10.1176/appi.ajp.2013.13030392.
    1. Romeo B, et al. Meta-analysis of short-and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015;230(2):682–688. doi: 10.1016/j.psychres.2015.10.032.
    1. Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi J-A, Richieri R, Courtet P, Abbar M. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231(18):3663–3676. doi: 10.1007/s00213-014-3664-5.
    1. McCloud TL, Caddy C, Jochim J, Rendell JM, Diamond PR, Shuttleworth C, Brett D, Amit BH, McShane R, Hamadi L, Hawton K, Cipriani A. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015; 29(9):CD011611. doi:10.1002/14651858.CD011611.pub2.
    1. Clements J, Nimmo W, Grant I. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982;71(5):539–542. doi: 10.1002/jps.2600710516.
    1. Perry EB Jr1, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O'Donnell E, Krystal JH, D'Souza DC; Yale Ketamine Study Group.Psychopharmacology. 2007;192(2):253–60.
    1. Caddy C AB, McCloud TL, Rendell JM, Furukawa TA, McShane R, Hawton K, A C. Ketamine and other glutamate receptor modulators for depression in adults (review). Cochrane Lib. 2015(9).
    1. Shiroma PR, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805–1813. doi: 10.1017/S1461145714001011.
    1. Murrough JWWL-B, Iacoviello B, Collins KA, Solon C, Glicksberg B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology. 2014;231:481–488. doi: 10.1007/s00213-013-3255-x.
    1. McGirr A, et al. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res. 2015;62:23–30. doi: 10.1016/j.jpsychires.2015.01.003.
    1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145. doi: 10.1016/j.biopsych.2009.08.038.
    1. Association AP. Diagnostic and statistical manual-text revision (DSM-IV-TR): American Psychiatric Association; 2000
    1. Dunne R, McLoughlin D. Regional Variation in Electroconvulsive Therapy Use. Ir Med J. 2011;104(3):84–87.
    1. Association WM. World Medical Association, Declaration of Helsinki: ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373.
    1. Group ICoHW . International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: 1996. 1996. ICH harmonised tripartite guideline: guideline for good clinical practice.
    1. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010;10:67doi: 10.1186/1471-2288-10-67.
    1. Cockrell J, Folstein M. Mini-mental state examination (MMSE) Psychopharmacol Bull. 1988;24(4):689.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. doi: 10.1016/S0006-3223(02)01866-8.
    1. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV axis I Disorders. Clinician Version (SCID-CV). Washington, D.C.: American Psychiatric Press, Inc., 1996.
    1. Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The Maudsley staging method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry. 2009;70(7):952–957. doi: 10.4088/JCP.08m04728.
    1. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9(1):97–113. doi: 10.1016/0028-3932(71)90067-4.
    1. Nelson HE, National Adult Reading Test (NART): For the Assessment of Premorbid Intelligence in Patients with Dementia: Test Manual, NFER-Nelson, Windsor, UK.
    1. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS) J Trauma Stress. 1998;11(1):125–136. doi: 10.1023/A:1024465317902.
    1. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10(3):799–812. doi: 10.2466/pr0.1962.10.3.799.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435. doi: 10.1192/bjp.133.5.429.
    1. Wisniewski SR, Rush AJ, Balasubramani G, Trivedi MH, Nierenberg AA, Investigators S Self-rated global measure of the frequency, intensity, and burden of side effects (PRISE) J Psychiatr Pract. 2006;12(2):71–79. doi: 10.1097/00131746-200603000-00002.
    1. Wechsler D, Laicardi C, Orsini A. WAIS-R: Wechsler adult intelligence scale revised: manual: OS; 1997.
    1. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999;14(2):167–177.
    1. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s cognitive examination III in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2013;36(3-4):242–250. doi: 10.1159/000351671.
    1. Kopelman MD, Wilson BA, Baddeley AD. The autobiographical memory interview: a new assessment of autobiographical and personal semantic memory in amnesic patients. J Clin Exp Psychol. 1989;11(5):724–744.
    1. Hodge B. ECT accreditation service (ECTAS) standards for the administration of ECT. R Coll Psychiatr. 2015. available at .
    1. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aus N Z J Psychiatry. 2013;47(8):710–727. doi: 10.1177/0004867413486842.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC medicine. 2010;8(1):1. doi: 10.1186/1741-7015-8-18.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere